Vera Therapeutics (NASDAQ: VERA) saw a 13% stock increase thanks to a bullish note from Cantor Fitzgerald’s Pete Stavropoulos, who predicts a $100 price target, three times the current value. The company’s progress in developing an IgA Nephropathy treatment could tap into a multi-billion-dollar market with a patient population of 85,000 to 151,000 in the U.S.

While biotech investments are risky, Vera’s potential in the IgAN market is promising, given the program’s progress and substantial addressable market. The Motley Fool Stock Advisor team did not include Vera Therapeutics in their 10 best stocks list, highlighting other potential high returns in the market.

Investors are encouraged to consider Stock Advisor’s track record of a 991% average return, outperforming the S&P 500’s 192%. Join an investing community focused on individual investors for top stock recommendations and potential high returns.

Read more at Yahoo Finance: Why Vera Therapeutics Stock Crushed it Today